Cite

HARVARD Citation

    He, W. et al. (2023). Regorafenib with or without a programmed cell death protein 1 antibody as third‐line treatment for microsatellite stable metastatic colorectal cancer. Cancer medicine. pp. 6488-6498. [Online]. 
  
Back to record